Drug
Dkb903
Dkb903: highest development phase Phase 1, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| DKB903 NCT07923747 | Phase 1 | Rheumatoid Arthritis and Systemic Lupus Erythematosus |
Latest
No recent events.
Follow Dkb903 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.